Morgan Stanley Pro Qr Therapeutics N.V. Call Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRQR
# of Institutions
65Shares Held
41.2MCall Options Held
26KPut Options Held
0-
Adage Capital Partners Gp, L.L.C. Boston, MA6.6MShares$15.7 Million0.02% of portfolio
-
Privium Fund Management B.V.5MShares$11.9 Million2.17% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.5MShares$8.33 Million1.2% of portfolio
-
Sio Capital Management, LLC New York, NY2.08MShares$4.94 Million2.02% of portfolio
-
Abrdn PLC1.85MShares$4.4 Million0.01% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $170M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...